

# Anti-NMDAR encephalitis for psychiatrists: the essentials

Matthew Beattie,<sup>1</sup>  John Goodfellow,<sup>1</sup> Maria Oto,<sup>1</sup> Rajeev Krishnadas<sup>2</sup>

BJPsych Bulletin (2022) 46, 235–241, doi:10.1192/bjb.2021.35

<sup>1</sup>Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, UK;  
<sup>2</sup>Stobhill Hospital, NHS Greater Glasgow & Clyde, UK

Correspondence to Matthew Beattie ([matthewwbeattie@outlook.com](mailto:matthewwbeattie@outlook.com))

First received 26 Aug 2020, final revision 14 Feb 2021, accepted 19 Mar 2021

© The Author(s), 2021. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists. This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.

Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis predominantly presents with psychiatric symptoms. Psychiatrists need to be alert to this diagnostic possibility, especially in female adolescents and young adults, as exemplified by the real (de-identified) case outlined below. Earlier diagnosis and immunotherapy improves long-term outcomes. Collaboration with neurology colleagues is essential for optimal care. ‘Red flags’ for autoimmune encephalitis and ‘diagnostic clues’ act as helpful aide memoires for this uncommon condition. The gold standard for testing is the detection of NMDAR antibodies in cerebrospinal fluid, but serum can be tested as a more accessible (but less reliable) preliminary step. The results of routine blood tests, magnetic resonance imaging of the head and electroencephalograms can be normal or show non-specific changes. Diagnostic criteria exist to define probable and definite cases. Immunotherapy for anti-NMDAR encephalitis is effective for many patients, but recovery is prolonged and relapses can occur.

**Keywords** Neuroimmunology; psychotic disorders; autoimmune encephalitis; neuropsychiatry; anti-NMDAR encephalitis.

## Case

A woman in her mid-20s, with no personal or family history of mental illness, presented to her general practitioner with anxiety and low mood. Sick leave from her stressful job provided no relief. Over 5 weeks, her mood, appetite and sleep rapidly worsened. She experienced severe panic attacks and later, an auditory hallucination on at least one occasion. Mirtazapine and zopiclone provided no immediate benefit, and an urgent referral to the community mental health team was made.

Her behaviour became acutely disturbed at home. She rapidly alternated between being angrily agitated and mutely staring. She spoke in strange voices, and the content could be nonsensical at times. Occasionally, she randomly burst into song. She repeatedly squatted and bit her lip. She followed her parents around the house, fearing harm could come to them. At different points in time, she complained of having a ‘sore head’ and ‘floppy’ legs.

Given the severe deterioration in her mental health, an emergency psychiatric admission using mental health legislation was arranged. On admission, routine physical observations (including temperature), examination and blood tests (including white cell count and C-reactive protein) were normal.

On the ward, she appeared profoundly depressed, with extremely impoverished and latent speech. At times, she also appeared fearfully hypervigilant or perplexed. She exhibited mutism, staring, stereotypy and mannerisms – features suggestive of catatonia. Her social judgement was impaired and she lacked insight. She required intense one-to-one nursing care and direction with washing and dressing, implying severe cognitive dysfunction (no formal testing was done).

The initial working diagnosis was a severe depressive episode with psychotic symptoms (ICD-10 code F32.3), given the prominence of her severely depressed mood, which preceded the disorganised behaviour, impoverished speech and psychomotor retardation.

Over 4 weeks on the ward, her mood partially lifted in response to treatment with venlafaxine, olanzapine (low dose) and regular lorazepam (for catatonia). After some uneventful passes home, early in-patient discharge was facilitated by her very supportive parents.

However, upon review in clinic a few days later, concerns were raised regarding an apparent worsening in her cognition (e.g. gross disorientation and poor memory) and motor skills, both fine (e.g. button opening) and gross (e.g. descending stairs). Furthermore, abnormal involuntary movements were observed in one hand.

Given the onset of new focal neurological deficits, it was decided to take blood tests to screen for autoimmune encephalitis. Fortuitously, results were returned within 24 hours (by the local neuroimmunology laboratory), and revealed the presence of serum N-methyl-D-aspartate receptor (NMDAR) antibodies.

Urgent admission to the neurology department was arranged, where work-up and treatment for probable anti-NMDAR encephalitis began. Cerebrospinal fluid (CSF) analysis also detected NMDAR antibodies, thereby confirming the diagnosis. Notably, magnetic resonance imaging (MRI) head and electroencephalogram (EEG) results were normal.

The encephalitis progressed despite treatment with steroids and intravenous immunoglobulins, resulting in fluctuating consciousness and autonomic instability for 1–2 weeks. Rituximab was then commenced, to which there was a gradual, marked and sustained response. Ovarian teratoma and other tumours were excluded through imaging. At 1 year after disease onset, the patient's recovery continued at home.

In **Box 1**, the patient in this case describes her experience.

## Learning objectives

- What is autoimmune encephalitis?
- What is anti-NMDAR encephalitis?
- When should anti-NMDAR encephalitis be suspected?
- How should suspected anti-NMDAR encephalitis be investigated?
- How should the practical management and treatment of anti-NMDAR encephalitis be approached?
- What is the prognosis for anti-NMDAR encephalitis?

## Autoimmune encephalitis

Autoimmune encephalitis refers to autoantibody-mediated inflammation of the brain. It manifests with a pattern of psychiatric and/or neurological symptoms, dependent on the specific autoantibody involved. Red flags for autoimmune encephalitis in patients with psychosis are shown in **Box 2**; these are useful when considering differential diagnoses, the indication for immunological testing and guiding discussion on the most suitable initial admitting speciality.

The number of known autoantibodies pathologically implicated in cases of autoimmune encephalitis expands every year, as new discoveries are made. Well-established ones include autoantibodies to the voltage-gated potassium channel (VGKC)-complexed proteins LGI1 and CASPR2, AMPA, and GABA<sub>B</sub>.<sup>4</sup> However, by far the most common type of autoimmune encephalitis, and the one most frequently associated with psychiatric symptoms at onset, is anti-NMDAR encephalitis.<sup>5</sup>

## Anti-NMDAR encephalitis

### Pathophysiology

In anti-NMDAR encephalitis, the action of immunoglobulin G (IgG) autoantibodies specific to the GluN1 subunit of the NMDA glutamate receptor results in overall glutamatergic hypofunction.<sup>6,7</sup> This causes disruption of cortical and sub-cortical network activity, even in the absence of notable structural neuronal injury.<sup>8</sup> The production of these autoantibodies can sometimes be triggered by an ovarian teratoma or infections (e.g. herpes simplex encephalitis); however, in the majority of cases the aetiology remains obscure.<sup>7,9</sup>

### Epidemiology

The demographic most commonly affected by anti-NMDAR encephalitis is female adolescents and young adults (median age 21 years; female:male ratio 8:2).<sup>10</sup> It is a rare condition, with an estimated incidence of just 1.5 cases per million per year.<sup>11</sup> Nevertheless, one in five cases in the UK (four in five in the USA<sup>6</sup>) presented to psychiatry first.<sup>7</sup> Therefore, it is important that psychiatrists working in all contexts know about this disease.

### Presentation

At first, a non-specific prodromal phase of flu-like symptoms (e.g. headache, fever, vomiting, diarrhoea and upper respiratory tract symptoms) occurs in the majority of cases.<sup>6</sup>

Within several days, wide-ranging psychiatric symptoms then develop, which typically prompts initial contact with health professionals. This highly variable phase usually

### Box 1. The experience of a patient with anti-N-methyl-D-aspartate receptor encephalitis (informed consent obtained).

I was in for a normal busy day at work, when I suddenly started to feel extremely overwhelmed and panicked. Stranger still, I completely blanked when I set about doing my usual work on the computer.

During my sick leave, having always been a very positive and social person, I was suddenly not interested in engaging with any of my friends or family. For instance, when my mum's hairdresser came over, someone I have always enjoyed chatting to, I avoided her entirely. I was also finding everyday tasks extremely difficult; for example, I couldn't wrap a towel around myself, I still had lots of shampoo and conditioner left in my hair when I came out of the shower, I couldn't put on my bra at all by myself and I kept putting two arms into a single top sleeve or two legs into a single trouser leg. Having always been a great sleeper, I was also finding it very difficult to sleep at night. I could not express to my parents how I was feeling and I couldn't fathom what was going on with me.

I grudgingly visited a local healthcare centre and met two psychiatrists who both told me I was severely depressed and then referred me to hospital, where I spent some time in the psychiatric ward. My mood initially was at the lowest it had been my entire life. I had no motivation to do anything at all. However, as stated, the doctor noticed my right hand twitching constantly, a physical behaviour I had never expressed prior to my admission, along with other symptoms, and made the decision to have my blood tested for autoimmune encephalitis.

It has been a long road towards recovery, most of which I do not remember, but over a year later I am still progressing and improving.

**Box 2.** Red flags for suspicion of autoimmune encephalitis in patients with psychosis (reproduced with permission from Pollak et al, based on work by Al-Diwani et al and Herken and Prüss).<sup>1–3</sup>

Red flags for suspicion of autoimmune encephalitis in patients with psychosis (one or more required):

- (a) Infectious prodrome
- (b) New-onset severe headache or clinically significant change in headache pattern
- (c) Rapid progression
- (d) Adverse response to antipsychotics or presence of neuroleptic malignant syndrome
- (e) Insufficient response to antipsychotics
- (f) Movement disorder (e.g. catatonia or dyskinesia)
- (g) Focal neurological disease
- (h) Decreased consciousness
- (i) Autonomic disturbance
- (j) Aphasia, mutism or dysarthria
- (k) Seizures
- (l) Presence of tumour or history of a recent tumour
- (m) Hyponatraemia (not explained by side-effects of medications)
- (n) Other autoimmune disorders (e.g. systemic lupus erythematosus, autoimmune thyroid disease)
- (o) Paraesthesia

**Box 3.** The mnemonic 'SEARCH For NMDAR-A' for diagnostic clues suggesting possible anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis (reproduced with permission from Dalmau et al).<sup>10</sup>

SEARCH For NMDAR-A:

- (a) **S**leep dysfunction (typically insomnia at disease onset)
- (b) **E**xcitement, disinhibition or manic behaviour alternating with depressive behaviour
- (c) **A**gitation or aggression
- (d) **R**apid onset (symptoms develop suddenly in days or weeks, whereas in acute psychosis there is usually a history of preceding behavioural changes)
- (e) **C**hildren and young adult predominance (median age at onset of 21 years; female:male ratio of 8:2)
- (f) **H**istory of psychiatric illness absent
- (g) **F**luctuating catatonia (periods of catatonia alternating with extreme agitation)
- (h) **N**egative and positive psychotic symptoms at presentation
- (i) **M**emory deficit
- (j) **D**ecrease of verbal output or mutism
- (k) **A**ntipsychotic drug intolerance
- (l) **R**ule out neuroleptic malignant syndrome
- (m) **A**ntibodies and additional paraclinical tests (electroencephalogram, magnetic resonance imaging or cerebrospinal fluid antibody testing) (NMDAR antibodies are always present in the cerebrospinal fluid)

lasts 1–2 weeks. It is marked by major coexisting psychopathology in the categories of behaviour, psychosis, mood, catatonia and sleep, with the complexity of psychiatric presentation being a consistent and distinctive feature of anti-NMDAR encephalitis.<sup>12</sup> The three most common presenting psychiatric symptoms are agitation (59%); psychosis (e.g. auditory/visual hallucinations, persecutory paranoid delusions and disorganised behaviour; 54%); and catatonia (42% in adults),<sup>13</sup> typically fluctuating between the classic bed-bound rigidity form and the hyperkinetic type. Major mood symptoms (e.g. anxiety, mood instability, depression and mania) are reported in a third of cases.<sup>13</sup> Short-term memory loss is considered a hallmark feature, but is often obscured by other symptoms.<sup>14</sup>

Subsequently, there is development of clear neurological features, such as seizures (e.g. generalised tonic-clonic and partial complex), dyskinesias and movement disorders (e.g. orofacial dyskinesia and choreoathetosis), severe cognitive dysfunction, autonomic instability (e.g. fluctuations in cardiac rhythm, thermoregulation and blood pressure), central hypoventilation, and fluctuating consciousness or coma.<sup>6,10</sup> In a large international cohort study of 577 cases, 77% of patients were admitted to an intensive care unit in the first month of illness; most often in cases where treatment is given late in the disease course.<sup>15</sup>

### Identification

Given the substantial overlap in the typical age at onset and the presenting symptoms of anti-NMDAR encephalitis with

primary psychiatric disorders (such as first-episode psychosis/schizophrenia and bipolar disorder), a pressing challenge for psychiatrists is its early identification,<sup>10</sup> which is made possible only if a high index of suspicion is applied from the outset. Timely diagnosis is especially important because prompt treatment with immunotherapy (e.g. started within 40 days of symptom onset) improves long-term outcomes.<sup>6,15</sup> In addition, early identification can minimise harm from use of antipsychotics, which are usually poorly tolerated in anti-NMDAR encephalitis and have been associated with neuroleptic malignant syndrome.<sup>16</sup>

To help promote earlier recognition of anti-NMDAR encephalitis in patients presenting with new-onset psychiatric symptoms, a mnemonic for diagnostic clues was conceived: 'SEARCH For NMDAR-A' (Box 3).<sup>10</sup>

### NMDAR antibody testing

Once the differential diagnosis of anti-NMDAR encephalitis is considered, the priority investigation should be to test for the presence of NMDAR antibodies in the (blood) serum. Practically, this is easily achievable in mental health settings by means of a simple blood draw in a yellow-/gold-topped (serum separating tube; SST) bottle. For gold-standard testing, a paired CSF sample should also be obtained (and tested) at the same time; however, it is acknowledged lumbar puncture mandates acute hospital admission, and for this

**Box 4.** Routine screening for autoantibodies in patients presenting with psychiatric symptoms.

Given the challenges of distinguishing the initial stages of autoimmune encephalitis from primary psychiatric disorders, there is a growing body of evidence researching the potential for routine screening for autoantibodies in patients presenting with psychiatric symptoms.<sup>17–20</sup> Thus far, drawing clear conclusions from this evidence has proven difficult, primarily because of study heterogeneity. Therefore, currently, there is no widely enacted recommendation or clinical guideline regarding routine autoantibody screening in the UK. However, a large, multi-site UK study is currently ongoing, which gives potential for change in the future.<sup>21</sup> Also of interest and linked to this study, a randomised controlled trial is investigating outcomes of immunotherapy (intravenous immunoglobulins and rituximab) in patients with ‘antibody-associated psychosis’.<sup>22</sup>

Notably, recently published clinical guidelines on schizophrenia in Australia, New Zealand and Germany recommend targeted autoantibody testing at initial presentation.<sup>23,24</sup>

reason, in reality, it is often tested at a later stage. Regarding the prospect of routine screening for autoantibodies in patients presenting with psychiatric symptoms, see [Box 4](#).

Importantly, rates of seropositivity of anti-NMDAR antibodies (of all Ig classes targeting GluN1, including IgG) in healthy individuals are surprisingly high, at over 10%.<sup>25</sup> Moreover, rates of seropositivity in healthy individuals are not significantly different from those in affected individuals; blood brain barrier permeability and activation of intrathecal antibody production are thought to be the major determining factors in whether disease develops.<sup>25–28</sup> Therefore, in practice, a positive serum result – even in a patient with psychosis – does not automatically equate to a diagnosis of anti-NMDAR encephalitis.<sup>29</sup> However, it does mean further investigation is warranted – at a minimum with CSF analysis, EEG and MRI of the head – and expert neurology evaluation should be sought.<sup>30</sup>

In the majority of anti-NMDAR encephalitis cases, both the serum and CSF have detectable NMDAR antibodies. However, at least one in ten cases are seronegative but CSF-positive.<sup>31,32</sup> Therefore, irrespective of the serum result in cases of high clinical suspicion, CSF testing is indicated to either support or exclude the diagnosis.

Other CSF findings in support of anti-NMDAR encephalitis are a lymphocytic pleocytosis, mildly raised protein concentration and presence of oligoclonal bands restricted to CSF (indicating intrathecal IgG synthesis).<sup>9,33</sup>

In conjunction with medical/neurology colleagues, careful consideration needs to be given to the practical challenges of safely conducting lumbar puncture (and MRI) in a patient who may be agitated and experiencing psychosis. Heavy sedation or general anaesthesia is sometimes required. Psychiatrists can help by ensuring the legal framework pertaining to detention, capacity and consent issues is satisfactorily addressed. Also, the provision of trained mental health nursing staff is conducive to optimising care.

Importantly, these challenges must be overcome to ensure equitable access to crucial investigations for all patients. The overwhelming benefits of early diagnosis and

correct treatment with immunotherapy must be prioritised throughout, regardless of the patient’s initial treating speciality or hospital location.

Currently, antibody testing via highly specialised national reference laboratories is the only option in many contexts, and can necessitate a turnaround time of several weeks. In the future, accessibility of testing will grow as local laboratories develop their own testing capabilities for the neuronal antibodies most commonly implicated in autoimmune encephalitis.<sup>34</sup>

If delay in obtaining results is encountered in the context of a patient with a worsening presentation (e.g. new neurological signs) and/or the suspicion of an organic aetiology is high, do not wait for the result.<sup>35</sup> Arrange a medical admission in liaison with neurology, so the patient can benefit from specialist evaluation (including other investigations) and monitoring, and preliminary treatment can be commenced.<sup>36</sup>

## Other investigations

Routine blood test results (including C-reactive protein and white cell count) are most often within normal limits in cases of anti-NMDAR encephalitis.<sup>37</sup> Neuroimaging results are also most often normal. For example, MRI of the head was found to be normal in 67–89% of cases.<sup>7,15</sup> When abnormalities are found, they are non-specific, e.g. mild or transient white matter changes in any region of the brain.<sup>38</sup> Compared with MRI, computed tomography imaging of the head provides inferior detail for detection of any central nervous system inflammatory changes that may be seen in autoimmune encephalitis, and therefore MRI is much preferred.<sup>39</sup> Notwithstanding, as a widely and rapidly accessible modality, computed tomography remains useful for urgent exclusion of gross central nervous system pathology, such as space-occupying lesions and intracranial haemorrhage. EEG findings are abnormal in 90% of anti-NMDAR encephalitis cases,<sup>15</sup> but are generally non-specific (focal or diffuse slowing, disorganised or epileptic activity). Nevertheless, it is suggested that an ‘extreme delta brush’ pattern is a unique feature of anti-NMDAR encephalitis.<sup>40</sup>

Crucially, therefore, normal results from any, or even all, of these investigations (routine blood tests, computed tomography, MRI and EEG) do not rule out a possible diagnosis of anti-NMDAR encephalitis. This reinforces the diagnostic importance of antibody testing in serum and CSF in suspected cases.

In confirmed anti-NMDAR encephalitis cases, whole-body imaging for tumours should be conducted.<sup>9,38</sup> Specifically, ovarian teratoma in female adolescents and young adults should be searched for by means of ultrasound scan and MRI of the pelvis.

## Diagnostic criteria

Clinical criteria for probable and definite anti-NMDAR encephalitis were developed by expert consensus in 2016, with the aim of advancing earlier diagnosis and immunotherapy ([Box 5](#)).<sup>41</sup>

Notably, these criteria adopt a neurology focus, giving rise to questioning of their practical utility for psychiatrists in a mental health setting.<sup>1</sup> Of specific concern is the fact

**Box 5.** Diagnostic criteria for anti-NMDAR encephalitis (reproduced with permission from Graus et al).<sup>41</sup>

Probable diagnosis of anti-NMDAR encephalitis

If all three criteria are met:

1. Rapid onset (less than 3 months) of at least four of the six following major groups of symptoms:

- (i) Abnormal (psychiatric) behaviour or cognitive dysfunction
- (ii) Speech dysfunction (pressured speech, verbal reduction, mutism)
- (iii) Seizures
- (iv) Movement disorder, dyskinesias or rigidity/abnormal postures
- (v) Decreased level of consciousness
- (vi) Autonomic dysfunction or central hypoventilation

2. At least one of the following laboratory study results:

- (i) Abnormal electroencephalogram (focal or diffuse slowing, disorganised activity, epileptic activity or extreme delta brush)
- (ii) Cerebrospinal fluid with pleocytosis or oligoclonal bands

3. Reasonable exclusion of other disorders

Definite diagnosis of anti-NMDAR encephalitis

Diagnosis can be made in the presence of one or more of the six major groups of symptoms and IgG anti-GluN1 antibodies, after reasonable exclusion of other disorders.

*(Antibody testing should include testing of cerebrospinal fluid. If only serum is available, confirmatory tests should be included (e.g. live neurons or tissue immunohistochemistry, in addition to cell-based assay)).*

that they do not support diagnosis in those presenting with primarily or exclusively psychiatric symptoms, despite evidence that such individuals exist.<sup>42</sup>

## Treatment of anti-NMDAR encephalitis

### Treatment of encephalitis

Thus far, treatment of anti-NMDAR encephalitis has been based on expert consensus experience (rather than higher-quality evidence such as randomised controlled trials).<sup>35,43</sup> On the whole, early and aggressive treatment results in better outcomes.<sup>44</sup>

First-line therapy is usually high-dose corticosteroids (initially intravenous then oral) and intravenous immunoglobulins or plasma exchange.<sup>43</sup> If there is an inadequate response (typically seen in 50% of cases<sup>15</sup>), rituximab (a monoclonal antibody treatment that targets B cells, thus reducing antibody production) is given as second-line therapy.<sup>45</sup> Cyclophosphamide is reserved as a further line of therapy in treatment-resistant cases.<sup>46</sup>

Parallel to immunotherapy, if a tumour (e.g. ovarian teratoma) is found, surgery is performed to excise it.<sup>43</sup>

### Acute behavioural management

Liaison neuropsychiatry may be called upon to advise on symptomatic management of agitation or psychosis, the mainstay of which will be ensuring the safety of the patient with specialist one-to-one nursing. As mentioned, detention

under mental health legislation and treatment under mental capacity legislation will likely be required.

Caution must be employed with regards to the use of psychotropic medication, as this can complicate the fluctuating clinical picture; for example, benzodiazepines may exacerbate respiratory depression and impaired consciousness.<sup>47–49</sup> In addition, there may be an association between use of antipsychotics and neuroleptic malignant syndrome in anti-NMDAR encephalitis.<sup>16</sup> Overall, these risks need to be balanced against the potential benefit of alleviating distressing symptoms and hazardous behaviour. Importantly, if antipsychotics are used, it is best to gradually discontinue them once the encephalitis is under control, so as to reduce the risk of metabolic side-effects (compounded by steroids).

### Prognosis

A validated predictive prognosis tool exists, called the anti-NMDAR Encephalitis One-Year Functional Status (NEOS) score.<sup>50</sup> It is scored on five categorical variables, with the presence of each worsening prognosis: intensive care unit admission, treatment delay of >4 weeks, lack of clinical improvement within 4 weeks, abnormal MRI and CSF white blood cell count of >20 cells/ $\mu$ L.

Following acute recovery from anti-NMDAR encephalitis, transfer to a specialist neuro-rehabilitation facility is often appropriate. Baseline and repeated neurocognitive assessments assist in comprehensive monitoring of the patient's functional recovery. Over 18 to 24 months, with treatment, eight out of ten cases make a gradual, but

significant recovery.<sup>15</sup> Prolonged deficits can include executive dysfunction, impulsivity, disinhibition and sleep abnormalities. Patients often have little memory of their illness.

Relapses occur (12% risk within 2 years), more often in cases not associated with a tumour at presentation, and the majority are of a less severe nature compared with the index illness.<sup>15</sup> Relapses require further treatment with immunotherapy. Notably, a quarter of relapses present with psychiatric symptoms only.<sup>42</sup> Therefore, psychiatrists need to be alert to this fact in someone with a past medical history of anti-NMDAR encephalitis.

## Case reflections

In retrospect, the case described many of the red flags for autoimmune encephalitis, and nearly all of the ‘SEARCH For NMDAR-A’ diagnostic clues were indeed present. This emphasises the importance of raising awareness of features suggestive of anti-NMDAR encephalitis among psychiatrists, to enable its early recognition.

Furthermore, this case demonstrates the importance of a fully comprehensive and systematic specialist work-up, including serum/CSF antibody testing, in suspected cases of anti-NMDAR encephalitis. In this instance, the patient’s MRI head and EEG results were normal, despite the relatively advanced stage of the encephalitis at the time of these investigations. The true diagnosis was only revealed by antibody testing of serum and CSF.

Finally, doctors must be mindful of the risk of diagnostic overshadowing in such cases where psychiatric and physical elements coexist, and be prepared to advocate for their patients to ensure they receive appropriate medical care.

## Conclusion

Anti-NMDAR encephalitis typically first presents with a complex constellation of acute-onset psychiatric symptoms, such as agitation, psychosis and catatonia. As in the case described, those with the condition can first present to psychiatry. Therefore, psychiatrists have a crucial role in the early recognition of anti-NMDAR encephalitis, and should be familiar with the features suggestive of it in the patient’s history, mental state and neurological examination. Clinical suspicion should trigger early discussion with neurology colleagues, and prompt testing of serum (and ideally CSF) for NMDAR antibodies. Collaborative working supports early diagnosis and timely immunotherapy, resulting in improved long-term outcomes.

In future, routine screening for autoantibodies in patients presenting with psychiatric symptoms may become common practice, and studies are ongoing assessing the potential role of immunotherapy within psychiatry.

## About the authors

**Matthew Beattie** is a specialty doctor with the Adult Mental Health Liaison Service at Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, Scotland, UK. **John Goodfellow** is a consultant neurologist based in the Neuroimmunology Laboratory at Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, Scotland, UK. **Maria Oto** is a consultant neuropsychiatrist with the Adult Mental Health Liaison Service at Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, Scotland, UK. **Rajeev Krishnadas** is a

consultant psychiatrist with Esteem (Early Intervention in Psychosis Service) at Stobhill Hospital, NHS Greater Glasgow & Clyde, Scotland, UK.

## Data availability

Data availability is not applicable to this article as no new data were created or analysed.

## Acknowledgement

Written informed patient consent was obtained for publication of the de-identified case, its discussion and [Box 1](#). We are grateful to the patient for kindly sharing her experience.

## Author contributions

M.B. developed the concept of the article, planned and prepared the initial draft, and was primarily responsible for subsequent redrafting and revision of the final manuscript. J.G., M.O., and R.K. provided expert input, and reviewed and edited the initial and final manuscript.

## Funding

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

## Declaration of interest

J.G. is Chief Executive Officer of Infimmune Ltd, a biotechnology company developing treatments for autoimmune disorders. The other authors have nothing to disclose.

## References

- Pollak TA, Lennox BR, Müller S, Benros ME, Prüss H, van Elst LT, et al. Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. *Lancet Psychiatry* 2020; **7**: 93–108.
- Al-Diwani A, Pollak TA, Langford AE, Lennox BR. Synaptic and neuronal autoantibody-associated psychiatric syndromes: controversies and hypotheses. *Front Psychiatry* 2017; **8**: 13.
- Herken J, Prüss H. Red flags: clinical signs for identifying autoimmune encephalitis in psychiatric patients. *Front Psychiatry* 2017; **8**: 25.
- Endres D, Maier V, Leyboldt F, Wandinger K-P, Lennox B, Pollak TA, et al. Autoantibody-associated psychiatric syndromes: a systematic literature review resulting in 145 cases. *Psychol Med* [Epub ahead of print] 7 Sep 2020. Available from: <https://doi.org/10.1017/S0033291720002895>.
- Rogers JP, Pollak TA, Blackman G, David AS. Catatonia and the immune system: a review. *Lancet Psychiatry* 2019; **6**(7): 620–30.
- Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. *Lancet Neurol* 2008; **7**(12): 1091–8.
- Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. *Brain* 2010; **133**: 1655–67.
- Finke C, Kopp UA, Scheel M, Pech L-M, Soemmer C, Schlichting J, et al. Functional and structural brain changes in anti-N-methyl-D-aspartate receptor encephalitis. *Ann Neurol* 2013; **74**: 284–96.
- Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. *Lancet Neurol* 2011; **10**(1): 63–74.
- Dalmau J, Armangué T, Planagumà J, Radosevic M, Mannara F, Leyboldt F, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. *Lancet Neurol* 2019; **18**(11): 1045–57.

- 11 Dalmau J, Tüzün E, Wu H-Y, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. *Ann Neurol* 2007; **61**: 25–36.
- 12 Al-Diwani A, Handel A, Townsend L, Pollak T, Isabel Leite M, Harrison PJ, et al. The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data. *Lancet Psychiatry* 2019; **6**: 235–46.
- 13 Sarkis RA, Coffey M J, Cooper JJ, Hassan I, Lennox B. Anti-N-methyl-D-aspartate receptor encephalitis: a review of psychiatric phenotypes and management considerations: a report of the American Neuropsychiatric Association Committee on Research. *J Neuropsychiatry Clin Neurosci* 2019; **31**: 137–42.
- 14 Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. *Brain* 2000; **123**(Pt 7): 1481–94.
- 15 Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. *Lancet Neurol* 2013; **12**(2): 157–65.
- 16 Lejste F, Thomas L, Picard G, Desestret V, Ducray F, Rogemond V, et al. Neuroleptic intolerance in patients with anti-NMDAR encephalitis. *Neurol Neuroimmunol Neuroinflamm* 2016; **3**(5): e280.
- 17 Scott JG, Gillis D, Ryan AE, Hargovan H, Gundarpi N, McKeon G, et al. The prevalence and treatment outcomes of antineuronal antibody-positive patients admitted with first episode of psychosis. *BJPsych Open* 2018; **4**(2): 69–74.
- 18 Lennox BR, Palmer-Cooper EC, Pollak T, Hainsworth J, Marks J, Jacobson L, et al. Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study. *Lancet Psychiatry* 2017; **4**(1): 42–8.
- 19 Bergink V, Armangue T, Titulaer MJ, Markx S, Dalmau J, Kushner SA. Autoimmune encephalitis in postpartum psychosis. *Am J Psychiatry* 2015; **172**(9): 901–8.
- 20 Steiner J, Walter M, Glanz W, Sarnyai Z, Bernstein H-G, Vielhaber S, et al. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. *JAMA Psychiatry* 2013; **70**(3): 271–8.
- 21 SINAPPS Group. *Prevalence of Pathogenic Antibodies in Psychosis (PPiP)2 Study*. SINAPPS Group, 2019 (<http://sinapps.org.uk/ppip2/4593809824>).
- 22 SINAPPS Group. *SINAPPS Research Projects: Investigating the Role of Antibodies in Psychosis*. SINAPPS Group, 2020 (<http://sinapps.org.uk/home/4594859629>).
- 23 Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. *Aust N Z J Psychiatry* 2016; **50**(5): 410–72.
- 24 Association of the Scientific Medical Societies in Germany (AWMF). *Clinical Practice Guidelines: Schizophrenia. Register Number 038 - 009*. AWMF Online, 2019 (<https://www.awmf.org/en/clinical-practice-guidelines/detail/038-009.html>).
- 25 Hammer C, Stepniak B, Schneider A, Papiol S, Tantra M, Begemann M, et al. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. *Mol Psychiatry* 2014; **19**: 1143–9.
- 26 Castillo-Gómez E, Oliveira B, Tapken D, Bertrand S, Klein-Schmidt C, Pan H, et al. All naturally occurring autoantibodies against the NMDA receptor subunit NR1 have pathogenic potential irrespective of epitope and immunoglobulin class. *Mol Psychiatry* 2017; **22**(12): 1776–84.
- 27 Ehrenreich H. Autoantibodies against the N-methyl-d-aspartate receptor subunit NR1: untangling apparent inconsistencies for clinical practice. *Front Immunol* 2017; **8**: 181.
- 28 Yu Y, Wu Y, Cao X, Li J, Liao X, Wei J, et al. The clinical features and prognosis of Anti-NMDAR encephalitis depends on blood brain barrier integrity. *Mult Scler Relat Disord* 2020; **47**: 102604.
- 29 Martinez-Martinez P, Titulaer MJ. Autoimmune psychosis. *Lancet Psychiatry* 2020; **7**(2): 122–3.
- 30 Pollak TA, Lennox BR. Time for a change of practice: the real-world value of testing for neuronal autoantibodies in acute first-episode psychosis. *BJPsych Open* 2018; **4**(4): 262–4.
- 31 Masdeu JC, Dalmau J, Berman KF. NMDA receptor internalization by autoantibodies: a reversible mechanism underlying psychosis? *Trends Neurosci* 2016; **39**(5): 300–10.
- 32 Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. *Lancet Neurol* 2014; **13**(2): 167–77.
- 33 Blinder T, Lewerenz J. Cerebrospinal fluid findings in patients with autoimmune encephalitis—a systematic analysis. *Front Neurol* 2019; **10**: 804.
- 34 Goodfellow JA, Mackay GA. Autoimmune encephalitis. *J R Coll Physicians Edinb* 2019; **49**(4): 287–94.
- 35 Rössling R, Prüss H. SOP: antibody-associated autoimmune encephalitis. *Neurol Res Pract* 2020; **2**: 1.
- 36 Venkatesan A, Geocadin RG. Diagnosis and management of acute encephalitis: a practical approach. *Neurol Clin Pract* 2014; **4**(3): 206–15.
- 37 Liu L, Liang J, Liu Q, Luo C, Liu J, Fan R, et al. Elevated plasma homocysteine levels in anti-n-methyl-d-aspartate receptor encephalitis. *Front Neurol* 2019; **10**: 464.
- 38 Lee SK, Lee S-T. The laboratory diagnosis of autoimmune encephalitis. *J Epilepsy Res* 2016; **6**(2): 45–50.
- 39 Granerod J, Davies NWS, Mukonoweshuro W, Mehta A, Das K, Lim M, et al. Neuroimaging in encephalitis: analysis of imaging findings and interobserver agreement. *Clin Radiol* 2016; **71**(10): 1050–8.
- 40 Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. *Neurology* 2012; **79**(11): 1094–100.
- 41 Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. *Lancet Neurol* 2016; **15**(4): 391–404.
- 42 Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. *JAMA Neurol* 2013; **70**(9): 1133–9.
- 43 Bartolini L. Practice current: how do you treat anti-NMDA receptor encephalitis? *Neurol Clin Pract* 2016; **6**(1): 69–72.
- 44 Nosadini M, Mohammad SS, Ramanathan S, Brilot F, Dale RC. Immune therapy in autoimmune encephalitis: a systematic review. *Expert Rev Neurother* 2015; **15**(12): 1391–419.
- 45 NHS England. *Clinical Commissioning Policy: Rituximab for Second Line Treatment for Anti-NMDAR Autoimmune Encephalitis (All Ages)*. NHS England, 2018 (<https://www.england.nhs.uk/publication/commissioning-policy-rituximab-for-second-line-treatment-for-anti-nmdar-auto-immune-encephalitis-all-ages/>).
- 46 Shin Y-W, Lee S-T, Park K-I, Jung K-H, Jung K-Y, Lee SK, et al. Treatment strategies for autoimmune encephalitis. *Ther Adv Neurol Disord* 2018; **11**: 1756285617722347.
- 47 Kuppaswamy PS, Takala CR, Sola CL. Management of psychiatric symptoms in anti-NMDAR encephalitis: a case series, literature review and future directions. *Gen Hosp Psychiatry* 2014; **36**(4): 388–91.
- 48 Mohammad SS, Jones H, Hong M, Nosadini M, Sharpe C, Pillai SC, et al. Symptomatic treatment of children with anti-NMDAR encephalitis. *Dev Med Child Neurol* 2016; **58**(4): 376–84.
- 49 Monteiro VL, Barreto FJN, Rocha PMB, do Prado PHT, Garcia FD, Correa H, et al. Managing severe behavioral symptoms of a patient with anti-NMDAR encephalitis: case report and findings in current literature. *Trends Psychiatry Psychother* 2015; **37**(1): 47–50.
- 50 Balu R, McCracken L, Lancaster E, Graus F, Dalmau J, Titulaer MJ. A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. *Neurology* 2019; **92**(3): e244–52.

